Table 1.

Clinical features and B-cell subsets of 25 patients with primary Sjögren syndrome (pSS) according the American–European Consensus Group (AECG)

Patients with pSS	AECG items*						Immunosuppressive drugs	Bm2+Bm2′/eBm5+Bm5
	I	II	III	IV	V	VI
1	+	+	−	+	+	−	MTX 15 mg/week	0.9
							PDN 6 mg/day
2	+	+	+	−	−	+	−	1.6
3	+	+	−	+	−	+	−	4.3
4	+	+	−	+	−	+	HCQ 400 mg/day	5.0
5	+	+	+	+	+	+	−	5.4
6	+	+	+	+	+	+	−	5.6
7	+	+	+	+	+	−	−	6.0
8	+	+	+	+	−	−	−	6.3
9	+	+	+	+	+	−	HCQ 400 mg/day	7.6
10	+	+	+	+	+	+	HCQ 400 mg/day	7.6
							PDN 5 mg/day
11	+	−	+	+	+	+	−	7.6
12	+	+	+	+	+	+	−	7.7
13	+	+	+	+	+	−	−	7.8
14	+	+	+	+	+	+	PDN 7 mg/day	8.4
15	+	+	+	−	+	+	−	9.1
16	+	+	+	−	−	+	HCQ 400 mg/day	9.6
17	+	+	−	+	+	+	−	9.6
18	+	+	−	+	−	+	−	12.6
19	+	+	+	−	+	+	−	13.7
20	+	+	−	+	−	+	HCQ 400 mg/day	14.6
21	+	+	+	+	+	+	HCQ 400 mg/day	16.0
22	+	+	+	+	+	+	−	16.3
23	+	+	+	+	+	+	−	18.8
24	−	+	+	+	+	+	−	29.6
25	+	+	+	+	+	+	−	35.2

*AECG items⁶: I, ocular symptoms; II, oral symptoms; III, objective ocular signs (Schirmer’s test ⩽5 mm in 5 min); IV, lip biopsy with focus score ⩾1; V, objective evidence of salivary gland involvement (unstimulated whole salivary flow ⩽1.5 ml in 15 min); VI, anti-SSA and/or anti-SSB. (+), item fulfilled; (−), item not fulfilled.

HCQ, hydroxychloroquine; MTX, methotrexate; PDN, prednisone.